Amarin did add this (below) after a few of us wrote in last year. My guess is they are waiting on Dr Mason's presentation to highlight the encapsulation patent and oxidation issues of generic Vascepa. Dr Nelson has an interesting presentation tomorrow that might touch on some comparisons.
"VASCEPA follows strict regulatory standards with a patented 3-month manufacturing process qualified to meet FDA drug standards. This process ensures the consistency and stability of VASCEPA. This is important because, if damaged, the safety and efficacy of the active ingredient can vary and is highly vulnerable to derivatives and oxidation/spoilage."
News 
Market Data 
Discover 
